Profile data is unavailable for this security.
About the company
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.
- Revenue in USD (TTM)0.00
- Net income in USD-288.96m
- Incorporated2019
- Employees70.00
- Location89Bio Inc142 Sansome Street, Second FloorSan Francisco 94104United StatesUSA
- Phone+1 (415) 432-9270
- Fax+1 (302) 655-5049
- Websitehttps://www.89bio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bicara Therapeutics Inc | 0.00 | -59.48m | 885.81m | 32.00 | -- | 1.93 | -- | -- | -1.13 | -1.13 | 0.00 | 9.37 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.36 | -- | -- | -- |
| Arrivent Biopharma Inc | 0.00 | -81.05m | 921.93m | 40.00 | -- | 3.33 | -- | -- | -2.62 | -2.62 | 0.00 | 8.24 | 0.00 | -- | -- | 0.00 | -34.15 | -- | -36.07 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| Septerna Inc | 840.00 | -10.27k | 924.06m | 68.00 | -- | -- | -- | 1,100,073.00 | -0.0003 | -0.0003 | 0.00002 | 0.0037 | -- | -- | -- | 12.35 | -- | -- | -- | -- | -- | -- | -792.86 | -- | -- | -- | 0.00 | -- | -- | -- | 102.06 | -- | -- | -- |
| Nuvation Bio Inc | 2.16m | -532.28m | 942.39m | 203.00 | -- | 1.87 | -- | 435.89 | -2.17 | -2.17 | 0.009 | 1.50 | 0.0036 | -- | 0.5936 | 42,392.16 | -88.53 | -16.27 | -94.44 | -16.65 | -32.38 | -- | -24,619.84 | -- | -- | -- | 0.0165 | -- | -- | -- | 27.25 | -- | -- | -- |
| Upstream Bio Inc | -100.00bn | -100.00bn | 974.92m | 38.00 | -- | -- | -- | -- | -- | -- | -- | 4.30 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | 96.37 | -- | -60.28 | -- | -- | -- |
| Lenz Therapeutics Inc | 0.00 | -60.04m | 976.28m | 6.00 | -- | 4.53 | -- | -- | -7.08 | -7.08 | 0.00 | 7.83 | 0.00 | -- | -- | 0.00 | -24.49 | -- | -25.55 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
| Vir Biotechnology Inc | 78.62m | -533.34m | 980.57m | 587.00 | -- | 0.7845 | -- | 12.47 | -3.92 | -3.92 | 0.5794 | 9.08 | 0.0444 | -- | -- | 133,931.90 | -30.10 | -0.6081 | -32.71 | -0.7192 | 98.78 | -- | -678.40 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Zymeworks Inc | 62.20m | -113.67m | 988.34m | 294.00 | -- | 2.73 | -- | 15.89 | -1.51 | -1.51 | 0.8306 | 5.23 | 0.1192 | -- | 1.37 | 228,672.80 | -21.79 | -22.58 | -25.64 | -26.90 | -- | -- | -182.75 | -91.17 | -- | -- | 0.00009 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| Cogent Biosciences Inc | 0.00 | -242.30m | 999.28m | 164.00 | -- | 4.94 | -- | -- | -2.48 | -2.48 | 0.00 | 2.85 | 0.00 | -- | -- | 0.00 | -65.53 | -49.53 | -74.36 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| Replimune Group Inc | 0.00 | -213.02m | 1.02bn | 331.00 | -- | 2.68 | -- | -- | -3.05 | -3.05 | 0.00 | 5.58 | 0.00 | -- | -- | 0.00 | -40.17 | -29.08 | -43.61 | -30.56 | -- | -- | -- | -- | -- | -- | 0.1577 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
| 89bio Inc | 0.00 | -288.96m | 1.03bn | 70.00 | -- | 2.46 | -- | -- | -2.91 | -2.91 | 0.00 | 3.56 | 0.00 | -- | -- | 0.00 | -62.93 | -45.50 | -67.67 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0859 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
| Gyre Therapeutics Inc | 191.34m | -76.96m | 1.05bn | 593.00 | -- | 15.33 | -- | 5.51 | -0.2281 | -0.2281 | 1.35 | 0.7366 | 2.83 | -- | 19.64 | 322,656.00 | -95.21 | -73.59 | -154.33 | -99.94 | 96.16 | -- | -33.64 | -205.62 | 3.29 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
| Applied Therapeutics Inc | -211.00k | -187.31m | 1.12bn | 37.00 | -- | 190.08 | -- | -- | -1.53 | -1.53 | -0.0017 | 0.0506 | -0.0028 | -- | -- | -8,440.00 | -246.85 | -140.37 | -- | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| Arcutis Biotherapeutics Inc | 138.71m | -195.54m | 1.19bn | 296.00 | -- | 7.57 | -- | 8.56 | -1.79 | -1.79 | 1.23 | 1.34 | 0.3799 | 1.04 | 3.49 | 468,608.10 | -53.55 | -65.64 | -75.79 | -71.72 | 89.57 | -- | -140.97 | -1,513.03 | 2.38 | -6.19 | 0.5664 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
Data as of Nov 25 2024. Currency figures normalised to 89Bio Inc's reporting currency: US Dollar USD
68.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 30 Sep 2024 | 15.11m | 14.27% |
| RA Capital Management LPas of 14 Nov 2024 | 14.18m | 13.38% |
| Suvretta Capital Management LLCas of 30 Sep 2024 | 7.99m | 7.55% |
| RTW Investments LPas of 30 Sep 2024 | 7.38m | 6.97% |
| BVF Partners LPas of 30 Sep 2024 | 6.81m | 6.43% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 6.78m | 6.40% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 4.88m | 4.61% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 3.25m | 3.07% |
| Pictet Asset Management SAas of 30 Sep 2024 | 3.25m | 3.07% |
| Westfield Capital Management Co. LPas of 30 Sep 2024 | 3.01m | 2.84% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
